Annexon Announces Pricing of $125.0 Million Underwritten Public Offering of Common Stock
- None.
- None.
The announcement by Annexon, Inc. regarding the pricing of an underwritten public offering is a significant financial event that warrants attention from investors and market analysts alike. The offering's structure, comprising both common stock and pre-funded warrants, is a strategic move to raise capital, with the company expecting gross proceeds of approximately $125.0 million. This influx of capital is crucial for Annexon's continued research and development in complement-mediated disorders, a specialized and growing field within biopharmaceuticals.
From a financial perspective, the pricing of the shares at $2.88 and the pre-funded warrants at a nearly identical price point suggests a calculated approach to attract investment without diluting share value excessively. The role of Jefferies and TD Cowen as joint book-running managers indicates a robust underwriting process, potentially enhancing investor confidence. However, the impact on current shareholders must be considered, as the introduction of new shares could lead to dilution of ownership percentages.
Long-term implications for stakeholders include the potential for accelerated product development and a stronger financial position to navigate the competitive landscape. Conversely, the costs associated with the offering and the inherent risk of clinical-stage ventures must be weighed against these benefits.
In the context of the biopharmaceutical industry, Annexon's focus on classical complement-mediated disorders places it within a niche yet critical area of medical research. The capital raised through this public offering is indicative of the company's stage in the clinical development cycle, which often requires substantial funding to progress through trials and towards regulatory approval.
Analyzing the potential return on investment involves assessing the company's pipeline, the prevalence of targeted conditions and the competitive landscape. The success of Annexon's complement medicines could disrupt standard treatment protocols, but this is contingent upon clinical efficacy and safety outcomes, regulatory hurdles and market acceptance. The use of a shelf registration statement, effective since May 2022, also highlights the company's preparedness to capitalize on favorable market conditions to secure funding.
It is essential to understand that the biopharmaceutical industry is subject to high volatility based on trial results and regulatory news. Thus, while this offering may bolster Annexon's financial footing, the inherent risks of drug development cannot be understated.
Annexon's use of a shelf registration statement for this public offering is a legal mechanism that allows the company to prepare for capital-raising activities in advance. This expedites the process of issuing new securities when market conditions are optimal. The SEC's role in declaring the registration statement effective ensures regulatory compliance and provides a layer of investor protection.
The offering's compliance with securities laws, including the provision of a prospectus supplement and the accompanying prospectus, is critical for transparency and informed investing. It's important to note that the press release explicitly states the offering's limitation to jurisdictions where it is lawful, a reminder of the varying securities regulations across states and countries.
For stakeholders, the legal framework surrounding this offering provides structure and clarity, reducing the legal risks associated with such transactions. However, potential investors should be diligent in reviewing the prospectus documents to understand fully the terms of the offering and the risks involved in investing in a clinical-stage biopharmaceutical company.
BRISBANE, Calif., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today announced the pricing of an underwritten public offering of 25,035,000 shares of its common stock and pre-funded warrants to purchase 18,379,861 shares of common stock. The shares of common stock are being sold at a price of
The total gross proceeds to Annexon are expected to be approximately
Jefferies and TD Cowen are acting as joint book-running managers for the offering.
The shares are being offered by Annexon pursuant to a shelf registration statement on Form S-3, including a base prospectus, that was filed with the Securities and Exchange Commission (SEC) and declared effective by the SEC on May 3, 2022. The offering is being made only by means of a prospectus supplement and the accompanying prospectus that will form a part of the registration statement. These documents can be accessed for free through the SEC’s website at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus, when available, may be obtained from: Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 547-6340, or by email at Prospectus_Department@Jefferies.com; or Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Attn: Prospectus Department, by telephone at (833) 297-2926 or by email at PostSaleManualRequests@broadridge.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Annexon
Annexon Biosciences (Nasdaq: ANNX) is a clinical-stage biopharmaceutical company utilizing a distinct scientific approach to stop C1q and all inflammatory aspects of classical complement pathway activation before it starts. As the only company solely focused on shutting down the early classical cascade, Annexon is developing a fit-for-purpose pipeline of therapeutics designed to provide meaningful benefits across multiple diseases of the body, brain and eye. With proof-of concept data in both Guillain-Barré syndrome and geographic atrophy, Annexon is rigorously advancing its mid-to late-stage clinical trials to bring their potential treatments to patients as quickly as possible.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “positioned,” “potential,” “predict,” “seek,” “should,” “suggest,” “target,” “on track,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. All statements other than statements of historical facts contained in this press release are forward-looking statements. These forward-looking statements include, but are not limited to, statements about the expected gross proceeds from the offering and the closing date of the offering. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but not limited to, risks and uncertainties related to, among other things, market conditions and the satisfaction of customary closing conditions related to the public offering. Risks and uncertainties relating to Annexon and its business can be found under the section titled “Risk Factors” contained in the preliminary prospectus supplement and the accompanying prospectus, the company’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q and the company’s other filings with the SEC. Any forward-looking statements that the company makes in this press release are made pursuant to the Private Securities Litigation Reform Act of 1995, as amended, and speak only as of the date of this press release. Except as required by law, the company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Contact:
Monique Allaire
THRUST Strategic Communications
monique@thrustsc.com
Media Contact:
Sheryl Seapy
Real Chemistry
949-903-4750
sseapy@realchemistry.com
FAQ
What did Annexon, Inc. (ANNX) announce?
What are the expected total gross proceeds from the offering?
When is the offering expected to close?
Who are the joint book-running managers for the offering?
Where can the documents related to the offering be accessed?
